<DOC>
	<DOCNO>NCT00862043</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy mid-term treatment sildenafil patient persistent moderate severe pulmonary hypertension ( PH ) heart valve intervention .</brief_summary>
	<brief_title>Sildenafil Secondary Pulmonary Hypertension Due Valvular Disease</brief_title>
	<detailed_description>Phase IV , prospective , multicenter , randomize , double-blind , placebo-controlled , academically fund clinical trial , 6 month follow-up . A total 354 patient recruit . Inclusion criterion : 1 ) successful surgical percutaneous repair cardiac valve least one year screen 2 ) persistent moderate severe PH , 3 ) absence residual significant valvular lesion . Patients randomize 1:1 receive sildenafil 40 mg t.i.d . placebo . The primary endpoint clinical composite score combining : all-cause mortality , hospital admission heart failure , World Health Organization ( WHO ) functional class , patient global assessment score . Additional clinical mechanistic secondary end-points define .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Age date selection ≥ 18 year Mean pulmonary pressure ≥ 30 mmHg , measure SwanGanz catheter place pulmonary artery Heart valve intervention : surgical percutaneous replacement , repair dilatation perform least one year inclusion Stable clinical condition least one month , without hospital admission heart failure , appropriate stable dos conventional cardiovascular medication Requiring likely require follow medication : organic nitrate , alphablocker therapy , potent cytochrome P450 3A4 inhibitor ( erythromycin , ketoconazole , cimetidine , HIV protease inhibitor ritonavir saquinavir ) Patients suffer myocardial infarction , stroke , lifethreatening arrhythmia within last 6 month . Patients rest hypotension , systolic blood pressure &lt; 90 mmHg Patients retinitis pigmentosa Anatomical deformation penis ( angulation , cavernosal fibrosis Peyronie 's disease ) patient condition may predispose priapism ( sickle cell anemia , multiple myeloma , leukemia ) Severe renal impairment creatinine clearance &lt; 30 ml/min Significant hepatic dysfunction Prosthesis valvular dysfunction hemodynamic repercussion . Pregnant breastfeed woman Patients unlikely cooperate study inability unwillingness give inform consent Life expectancy le 2 year due noncardiac disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Secondary Pulmonary Hypertension</keyword>
	<keyword>Valvular Heart Disease</keyword>
	<keyword>Phosphodiesterase-Inhibitors</keyword>
	<keyword>Sildenafil</keyword>
	<keyword>Outcomes Research</keyword>
</DOC>